Treg specialist to advance clinical research with cGMP nod

11 March 2024
cdmo_cmo_manufacturing_biotech_big

Polish cell therapy company PolTREG (WSE: PTG) has received a Current Good Manufacturing Practice (cGMP) certificate, allowing it to produce advanced therapies at its own facility.

Shares in the clinical-stage biotech, which is focused on cell therapies for a range of autoimmune diseases, ticked up around 3% on Monday morning.

The company is looking to lead in the area of T-regulatory cells (Tregs), with its most advanced candidate, PTG-007, in mid-stage testing for early-onset Type-1 diabetes (T1D).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology